UAB / UMN SPORE in Pancreatic Cancer

胰腺癌中的 UAB / UMN SPORE

• 批准号: 7939097
• 负责人: DONALD J. BUCHSBAUM
• 金额: $ 230万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-16 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7939097
• 关键词: UAB; UMN; SPORE; Pancreatic; Cancer

Six years ago, our UAB SPORE in Pancreatic Cancer application was partially funded via a P-20 grant. With limited funding; our mini-SPORE was composed of 2 major projects, 3 Cores and a Developmental Research Program. During this initial funding period, translation of SPORE science resulted in two phase I trials, one Phase II trial and a novel MRI imaging trial. The investigators of the SPORE have 88 publications relating to SPORE projects or pancreatic cancer. The Developmental Research funding resulted in two major projects, Projects 1, & 4 in this renewal application and 2 awardees becoming Project co-leaders. Three years ago, Dr. Vickers (SPORE PI) became Chairman of Surgery at the University of Minnesota (UMN) and we restructured into a joint UAB/UMN SPORE in Pancreatic Cancer. The joint SPORE has functioned well and this proposal is our amended competitive renewal for full SPORE funding (PSO application). This proposal has 4 major projects: Project 1 is utilizing proteomic techniques in transgenic animal models to identify biomarkers that are predictive of early stage pancreatic cancer; Project 2 is a continuation project which is examining multiple methods to enhance the therapeutic efficacy of anti-DR5 monoclonal antibodies in pancreatic cancer animal models and patients; Project 3 is utilizing genomic and genetic data obtained from human pancreatic cancer (PCa) samples and observations from mouse models of PCa to understand the genetic events that drive metastasis and treatment resistance in this disease. These studies will lead to a phase I clinical trial; Project 4 is engineering novel conditionally replicative adenoviral vectors that target pancreatic cancer stem cell-like tumor cells for the treatment of metastatic pancreatic cancer. The four important and effective Cores are: 1) Administration; 2) Tissue Resource and Molecular Pathology; 3) Biostatistics; and 4) Clinical Management and Trials (Advocacy Sub-Core). We also request support for continuation of our Developmental Research and Career Development Programs which includes Morehouse School of Medicine and Tuskegee University. The application has strong institutional support from UAB and UMN, excellent pancreatic cancer populations and concurrence with federal guidelines.

六年前，我们在胰腺癌应用中使用的UAB孢子是通过P-20赠款部分资助的。资金有限；我们的迷你杂物由2个主要项目，3个核心和一个发展研究计划组成。在此最初的资金期间，孢子科学的翻译导致了两个I期试验，一项II期试验和一项新型MRI成像试验。孢子的研究人员有88个出版物与孢子项目或胰腺癌有关。在此续签申请中，发展研究资金导致了两个主要项目，项目1和4，并获得了2名获奖者成为项目共同领导者。三年前，维克斯（Vickers）博士（孢子PI）成为明尼苏达大学（UMN）手术主席，我们重组为胰腺癌的UAB/UMN孢子联合。联合孢子的运作良好，该提案是我们对全孢子资金（PSO应用程序）的修订竞争性更新。该提案有4个主要项目：项目1正在利用转基因动物模型中的蛋白质组学技术来识别预测早期胰腺癌的生物标志物；项目2是一个延续项目，它正在研究多种方法，以增强胰腺癌动物模型和患者中抗DR5单克隆抗体的治疗功效；项目3正在利用从人胰腺癌（PCA）样品获得的基因组和遗传数据，并从PCA小鼠模型中进行观察来了解驱动转移和治疗耐药性的遗传事件。这些研究将导致I期临床试验。项目4是有条件地重复腺病毒载体的新型新型，靶向胰腺癌干细胞样肿瘤细胞以治疗转移性胰腺癌。四个重要且有效的核心是：1）给药； 2）组织资源和分子病理； 3）生物统计学； 4）临床管理和试验（倡导子核）。我们还要求支持继续我们的发展研究和职业发展计划，其中包括Morehouse医学院和Tuskegee University。该应用程序得到了UAB和UMN的大力机构支持，出色的胰腺癌人群以及与联邦准则一致。